Kilitch Drugs India Ltd (BSE: 524500) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹702 Cr, it ranks #1,806 by market cap among the 6,197 Indian listed companies on FinBizNet, and #52 of 86 in Medicinal Chemicals and Botanical Products. At ₹215.52 (as of 16 Nov 2026), the share price is 19.6% below its 52-week high of ₹267.90 and 83.8% above its 52-week low of ₹117.25. The share price is up 13.4% over one year and up 12.5% over three months.
| Current Price | ₹215.52 |
|---|---|
| Market Cap | ₹702 Cr |
| BSE Code | 524500 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 22.5 |
| Return on Equity | 12.36% |
| Return on Assets | 5.56% |
| 52-Week Range | ₹117.25 – ₹267.90 |
| 1-Year Price Change | +13.4% |
| 3-Month Price Change | +12.5% |
| Beta (1Y) | 0.24 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | kilitch.com |
| Revenue | ₹50 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 2.8% |
| EPS (Basic) | ₹0.64 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Kilitch Drugs India Ltd reported revenue of ₹50 Cr in Q2 FY27, up 2.7% from ₹49 Cr in Q2 FY26 and up 11.9% from ₹45 Cr in Q1 FY27. It posted a net profit of ₹1 Cr for the quarter, against a net profit of ₹8 Cr in Q2 FY26 (down 82.5%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹43 Cr (Q1 FY26) to ₹90 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹50 Cr | ₹1 Cr | 2.8% |
| Q1 FY27 | ₹45 Cr | ₹2 Cr | 4.4% |
| Q4 FY26 | ₹90 Cr | ₹15 Cr | 16.6% |
| Q3 FY26 | ₹54 Cr | ₹4 Cr | 8.0% |
| Q2 FY26 | ₹49 Cr | ₹8 Cr | 16.4% |
| Q1 FY26 | ₹43 Cr | ₹2 Cr | 5.2% |
| Q4 FY25 | ₹61 Cr | ₹10 Cr | 16.7% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 63.77% of Kilitch Drugs India Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 49.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional produ
1. Development and Operations of Pharmaceutical Business-This segment engages in the development and operation of pharmaceutical business.
1. Development and Operations of Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Kilitch Drugs India Ltd | ₹702 Cr | 22.5 | 12.36% | ₹50 Cr | +13.4% |
Listed by market capitalisation. Ratios are shown for context only.
Kilitch Drugs India Ltd is trading at ₹215.52, with a market capitalisation of ₹702 Cr.
Kilitch Drugs India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Kilitch Drugs India Ltd has a P/E of 22.5 and a return on equity of 12.36%.
Kilitch Drugs India Ltd is listed on the BSE under the scrip code 524500.
Kilitch Drugs India Ltd's share price is up 13.4% over one year and up 12.5% over three months. Its 52-week range is ₹117.25 to ₹267.90.
In Q2 FY27, Kilitch Drugs India Ltd reported revenue of ₹50 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.64 (consolidated, parsed from the company's exchange filing).
Kilitch Drugs India Ltd reported revenue of ₹50 Cr in Q2 FY27, up 2.7% from ₹49 Cr in Q2 FY26 and up 11.9% from ₹45 Cr in Q1 FY27.
Promoters held 63.77% of Kilitch Drugs India Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.